CN100551370C - 雷诺嗪在制备治疗糖尿病的药物组合物中的应用 - Google Patents

雷诺嗪在制备治疗糖尿病的药物组合物中的应用 Download PDF

Info

Publication number
CN100551370C
CN100551370C CNB038113236A CN03811323A CN100551370C CN 100551370 C CN100551370 C CN 100551370C CN B038113236 A CNB038113236 A CN B038113236A CN 03811323 A CN03811323 A CN 03811323A CN 100551370 C CN100551370 C CN 100551370C
Authority
CN
China
Prior art keywords
ranolazine
isomer
pharmaceutically acceptable
acceptable salt
racemic mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038113236A
Other languages
English (en)
Chinese (zh)
Other versions
CN1652788A (zh
Inventor
安德鲁·沃尔夫
马库斯·耶林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1652788A publication Critical patent/CN1652788A/zh
Application granted granted Critical
Publication of CN100551370C publication Critical patent/CN100551370C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB038113236A 2002-05-21 2003-05-21 雷诺嗪在制备治疗糖尿病的药物组合物中的应用 Expired - Fee Related CN100551370C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38278102P 2002-05-21 2002-05-21
US60/382,781 2002-05-21
US45933203P 2003-03-31 2003-03-31
US60/459,332 2003-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910171670A Division CN101658673A (zh) 2002-05-21 2003-05-21 治疗糖尿病的方法

Publications (2)

Publication Number Publication Date
CN1652788A CN1652788A (zh) 2005-08-10
CN100551370C true CN100551370C (zh) 2009-10-21

Family

ID=29586970

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038113236A Expired - Fee Related CN100551370C (zh) 2002-05-21 2003-05-21 雷诺嗪在制备治疗糖尿病的药物组合物中的应用

Country Status (16)

Country Link
US (4) US20040063717A1 (enExample)
EP (2) EP1505977B1 (enExample)
JP (1) JP4546824B2 (enExample)
KR (1) KR101030943B1 (enExample)
CN (1) CN100551370C (enExample)
AU (1) AU2003248558B8 (enExample)
BR (1) BR0311161A (enExample)
CA (1) CA2486712C (enExample)
ES (1) ES2523873T3 (enExample)
IL (4) IL165304A0 (enExample)
MX (1) MXPA04011530A (enExample)
NO (1) NO330336B1 (enExample)
NZ (1) NZ536678A (enExample)
RU (1) RU2320343C2 (enExample)
WO (1) WO2003099281A2 (enExample)
ZA (1) ZA200409331B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
BRPI0606403A2 (pt) * 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
MX2009010895A (es) * 2007-04-12 2009-10-26 Cv Therapeutics Inc Ranolazina para aumentar la secrecion de insulina.
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20110280941A1 (en) * 2008-12-11 2011-11-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805463A1 (fr) * 2000-02-25 2001-08-31 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
CN1321088A (zh) * 1998-09-10 2001-11-07 Cv治疗公司 雷诺嗪持续释放制剂

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0283168A3 (en) * 1987-03-16 1989-06-14 American Home Products Corporation Fluorooxirane carboxylates
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DK0407780T3 (da) 1989-06-23 1996-09-30 Syntex Inc Ranolazin og beslægtede piperaziner til anvendelse i behandling af væv, der har været udsat for fysisk eller kemisk skade
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CA2339088A1 (en) * 1998-08-11 2000-02-24 The Governors Of The University Of Alberta Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6528511B2 (en) 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
CN1462191B (zh) 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
CA2415826A1 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
CA2434436A1 (en) 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
ATE292633T1 (de) * 2001-07-19 2005-04-15 Cv Therapeutics Inc Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
US6958352B2 (en) 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
AU2004217441A1 (en) 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP
EP2377528B1 (en) 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005115379A2 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2006053161A1 (en) 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
BRPI0606403A2 (pt) 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
AU2006223212A1 (en) 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
JP2010514696A (ja) 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
US20080248112A1 (en) 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
WO2008150565A2 (en) 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
EA201070914A1 (ru) 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20100056536A1 (en) 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
US20100130436A1 (en) 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
AU2010248948A1 (en) 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321088A (zh) * 1998-09-10 2001-11-07 Cv治疗公司 雷诺嗪持续释放制剂
FR2805463A1 (fr) * 2000-02-25 2001-08-31 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APPARENT REVERSAL OF INSULIN RESISTANCE INCARDIAC MUSCLE IN ALLOXAN DIABETES BY 2 BROMOSTEARATE. RANDLE P J.NATUER(LONDON),Vol.221 No.5182. 1969 *
DATABASE BIOSIS‘Online!BIOSCIENCESINFORMATIONTHE LONGITUDINAL EFFECT OFINHEBITING FATTYACID OXIDATION IN DEABETIC RATSFED A HIGH FATDIET. BARNETT M ET AL.BIOSCIENCES INFORMATION SERVICE PHILADELPHIA. 1992 *

Also Published As

Publication number Publication date
MXPA04011530A (es) 2005-08-15
CA2486712C (en) 2012-01-03
US20040063717A1 (en) 2004-04-01
EP1505977A2 (en) 2005-02-16
US8314104B2 (en) 2012-11-20
EP1505977B1 (en) 2014-09-10
IL165304A0 (en) 2006-01-15
US20100197701A1 (en) 2010-08-05
IL213806A0 (en) 2011-07-31
IL213809A0 (en) 2011-07-31
WO2003099281A2 (en) 2003-12-04
US20140378465A1 (en) 2014-12-25
IL165304A (en) 2011-08-31
KR101030943B1 (ko) 2011-04-28
BR0311161A (pt) 2005-03-29
RU2320343C2 (ru) 2008-03-27
CA2486712A1 (en) 2003-12-04
HK1073441A1 (en) 2005-10-07
EP2332540A1 (en) 2011-06-15
JP2005532331A (ja) 2005-10-27
RU2004133670A (ru) 2005-06-10
AU2003248558B8 (en) 2009-07-09
ZA200409331B (en) 2005-06-29
NZ536678A (en) 2007-01-26
US20130102555A1 (en) 2013-04-25
NO330336B1 (no) 2011-03-28
AU2003248558B2 (en) 2009-03-12
ES2523873T3 (es) 2014-12-02
WO2003099281A3 (en) 2004-04-01
CN1652788A (zh) 2005-08-10
KR20040111677A (ko) 2004-12-31
JP4546824B2 (ja) 2010-09-22
NO20045554L (no) 2004-12-20
AU2003248558A1 (en) 2003-12-12
US8883750B2 (en) 2014-11-11

Similar Documents

Publication Publication Date Title
CN100551370C (zh) 雷诺嗪在制备治疗糖尿病的药物组合物中的应用
US6677342B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
KR910004571B1 (ko) 경구용 당뇨병치료 제제를 제조하는 방법
CN101516347A (zh) 包含二甲双胍和瑞格列奈的药物制剂
JP5452843B2 (ja) 夜間の経口インスリン治療
US8822473B2 (en) Method of treating diabetes
TW455491B (en) Pharmaceutical composition for oral administration
JP2010528112A (ja) 糖尿病を治療する方法
JP2008543723A (ja) ロシグリタゾンを含む経口製剤
CN101658673A (zh) 治疗糖尿病的方法
RU2442585C2 (ru) Способ лечения диабета
HK1073441B (en) Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100519

Address after: American California

Patentee after: Cv Therapeutics Inc.

Address before: American California

Patentee before: CV Therapeutics Inc.

ASS Succession or assignment of patent right

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER: GILEAD PALO ALTO, INC.

Effective date: 20120428

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120428

Address after: American California

Patentee after: Gilead Sciences Corporation

Address before: American California

Patentee before: Cv Therapeutics Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091021

Termination date: 20200521

CF01 Termination of patent right due to non-payment of annual fee